Does continuing ACE-I or ARB therapy reduce all-cause mortality compared to discontinuation in persons with low estimated glomerular filtration rate?
Continuing ACE-I or ARB therapy in patients with declining kidney function may provide cardiovascular benefits without increasing the risk of end-stage kidney disease.
The findings suggest that continuing ACE-I or ARB therapy in patients with declining kidney function may be associated with cardiovascular benefit without excessive harm of ESKD.
Qiao et al. (Mon,) studied this question.